^
Association details:
| Biomarker: | Chr t(11;14) |
|---|---|
| Cancer: | Multiple Myeloma |
| Regimen: | VenVd (bortezomib + dexamethasone injection + Venclexta (venetoclax)) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Published date:
02/03/2021
Excerpt:
Recommendations: Patients who receive second-line therapy: VenVd is a suitable option for patients with t(11;14) who have failed lenalidomide and are sensitive to PIs [I, A], if available….Patients at third and subsequent lines of treatment: Patients with t(11;14), who are refractory to lenalidomide and are PI-sensitive may be treated with VenVd [I, A], if available.
DOI:
10.1016/j.annonc.2020.11.014
